250
Participants
Start Date
August 1, 2017
Primary Completion Date
October 20, 2024
Study Completion Date
February 28, 2025
V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine
The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
Saline
Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
CHUM, Montreal
Merck Sharp & Dohme LLC
INDUSTRY
International Development Research Centre, Canada
OTHER_GOV
Dalhousie University
OTHER
Université de Montréal
OTHER
Coalition for Epidemic Preparedness Innovations
OTHER
Cecile Tremblay
NETWORK